BACKGROUND Super-absorbent diaper is a disposable diaper with new technology which has a soft-airy structure, breathable sheet, and rich absorbent core. This study aimed to compare the safety and efficacy of super-absorbent diaper with standard absorbent diaper. METHODS A single-blinded, randomized, controlled, cross-over study was performed in 324 months babies. A safety study was performed in 113 babies without diaper rash (group A: super-absorbent to standard and B: standard to super-absorbent) and efficacy study in 59 babies with mild-to-moderate diaper rash (group C: super-absorbent to standard and D: standard to super-absorbent). Each group used super-absorbent or standard diaper for 2 weeks. Skin assessment scores (SAS) were recorded at baseline, week-2, and week-4. Non-parametric tests were used to analyze the data. RESULTS In the safety study, there was no significant increase of SAS in group A at week-2 and -4, but in group B there was a significant increase of SAS (1.9 to 4.1, p = 0.001) at week-2 with a significant reduction at week-4 (4.1 to 2.2, p<0.001). In the efficacy study, there was a reduction of SAS at week-2 in group C (p = 0.07) and D (p = 0.05). However, SAS increased in group C (6.4 to 8.3, p = 0.2) and decreased in group D (8.6 to 6.1, p = 0.13) at week-4. Super-absorbent diaper showed a significant reduction of SAS in the pubic areas (1.43 to 0.73, p<0.011). CONCLUSIONS The new super-absorbent diaper is safe to use and may have efficacy in the improvement of skin conditions and diaper rash, especially in the pubic areas.
Generalized pustular psoriasis (GPP) is a rare, severe form of psoriasis that may be associated with monogenic autoinflammatory disorders such as deficiency of interleukin-36 receptor antagonist (DITRA). We report 2 Indonesian siblings with infantile-onset erythrodermic GPP caused by homozygous IL36RN c.115 + 6T>C mutations, representing the first genetically confirmed familial DITRA cases from Indonesia. The elder sister developed recurrent pustular flares from early infancy that progressed to chronic erythroderma with acrodermatitis continua of Hallopeau (ACH). The younger sibling presented at 8 months of age with widespread pustular eruptions and early ACH. Genetic testing confirmed homozygosity for the pathogenic variant in both siblings, while their parents and brother were heterozygous carriers. Both patients demonstrated hallmark features of DITRA, including early onset, acral pustulosis, and chronic relapsing disease. Conventional systemic therapies provided only partial control, highlighting therapeutic limitations in resource-limited settings where biologics such as secukinumab remain inaccessible. These cases add to the limited reports of DITRA from Southeast Asia and underscore the importance of genetic testing in early-onset GPP for accurate diagnosis, family counseling, and consideration of targeted therapy.